Halopril tablets are indicated for:
Schizophrenia: treatment of symptoms and prevention of relapse. Other psychoses, especially paranoid. Mania and hypomania. Mental and behavioral disorders, such as aggression, hyperactivity and a tendency to self-mutilation in mentally retarded patients and in patients with organic brain lesions. Adjunctive therapy in the short-term treatment of moderate to severe psychomotor agitation. Nausea and vomiting.
Composition
Active ingredient: haloperidol;
1 tablet contains haloperidol - 1.5 mg;
Excipients: croscarmellose sodium; microcrystalline cellulose, lactose monohydrate, corn starch, colloidal silicon dioxide, magnesium stearate, macrogol 4000.
Contraindication
Hypersensitivity to any of the components of the drug. Coma, patients with severe depression from alcohol or other substances acting on the central nervous system, endogenous depressions without impairment, Parkinson's disease. Asthenia, neuroses and spastic states due to damage to the basal ganglia (hemiplegia, multiple sclerosis). Severe clinical heart diseases. Persons with a hereditary predisposition to arrhythmias or to arrhythmias of the "pirouette" type. Untreated hypokalemia. Simultaneous use of drugs that prolong the QT interval; depression, kidney and liver diseases with severe impairment of their functions. Known or suspected pregnancy, breastfeeding. Parenteral use in children.
Method of application
Take orally during or after meals, with a full glass of water.
The dosage of the drug for all indications should be established individually under the supervision of a physician. The initial dose should take into account the patient's age, severity of symptoms and previous response to neuroleptics.
Elderly or debilitated patients who have previously had adverse reactions to neuroleptics may require a lower dose of haloperidol. The initial dose should be half the usual adult dose and then titrated to achieve the optimal response to therapy. Liver function should be monitored; the dose should be reduced in the presence of hepatic impairment.
Haloperidol should be administered at the lowest clinically effective dose.
Application features
Pregnant women
Contraindicated.
Children
Contraindicated.
Drivers
Contraindicated.
Overdose
In case of overdose, the main symptoms are intense extrapyramidal reactions, hypotension and sedation. Extrapyramidal reactions manifest as muscle rigidity and generalized or localized tremor.
In severe cases, the patient may become comatose with respiratory depression and severe hypotension, which may lead to a shock-like state. The risk of ventricular arrhythmias, possibly associated with prolongation of the QT interval on the electrocardiogram, should also be considered.
There is no specific antidote. Treatment is mainly supportive.
Side effects
When using Halopril with other drugs of the same class, isolated cases of QT prolongation, ventricular arrhythmias such as torsades de pointes, ventricular tachycardia, ventricular fibrillation and cardiac arrest have been observed.
Interaction
If enzyme inducers such as carbamazepine, phenobarbital, rifampicin are added to long-term treatment while taking Halopril, this may lead to a significant decrease in the level of haloperidol in the blood plasma. Therefore, during combined treatment, the dose of Halopril should be adjusted if necessary. After stopping the intake of such drugs, it may be necessary to reduce the dose of Halopril.
Sodium valproate, a drug known as a glucuronidation inhibitor, does not affect the plasma levels of haloperidol.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C.
Shelf life - 3 years.
